Normal view MARC view ISBD view

BTG1, a member of a new family of antiproliferative genes. [electronic resource]

By:

Rouault, J P

Contributor(s):

Producer: 19920515Description: 1663-70 p. digitalISSN:

0261-4189

Subject(s): Online resources:

Available from publisher's website

In: The EMBO journal vol. 11

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

There are no comments on this title.

to post a comment.

Back to results

21 Rethinking methadone for the management of chronic pain.
by Reisfield, Gary M
22 Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.
by Yadav, Jaydeep
23 Amenamevir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers.
by Adeloye, Temitope
24 Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors.
by Wang, Ying-Hong
25 Kuypers and Vanhove reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker.
by Kuypers, Dirk R J
26 Porcine cytochrome P450 3A: current status on expression and regulation.
by Rasmussen, Martin Krøyer
27 Binding of furanocoumarins in grapefruit juice to Aspergillus niger hyphae.
by Myung, Kyung
28 Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro.
by Greenblatt, David J
29 Assessment of oral midazolam limited sampling strategies to predict area under the concentration time curve (AUC) during cytochrome P450 (CYP) 3A baseline, inhibition and induction or activation.
by Ma, J D
30 Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition.
by Zientek, Michael
31 Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activation.
by Nguyen, Anh N
32 The computational model to predict accurately inhibitory activity for inhibitors towards CYP3A4.
by Xie, Zhiyuan
33 Effect of botanical immunomodulators on human CYP3A4 inhibition: implications for concurrent use as adjuvants in cancer therapy.
by Patil, Dada
34 Clinically significant drug-drug interactions between tramadol and CYP3A4 inhibitors: disproportionality analysis in VigiBase® and hypothesis on the underlying mechanism.
by Delafoy, Clémence
35 High throughput quantitative assessment of CYP inactivation using 2 concentration points.
by Albaugh, Daniel
36 Cytochrome P450 3A4 inhibition by ketoconazole: tackling the problem of ligand cooperativity using molecular dynamics simulations and free-energy calculations.
by Bren, Urban
37 Enzymatic and Nonenzymatic Electrochemical Interaction of Abiraterone (Antiprostate Cancer Drug) with Multiwalled Carbon Nanotube Bioelectrodes.
by Aliakbarinodehi, Nima
38 Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy Subjects.
by Newman, Joseph V
39 CYP3A4 inducer and inhibitor strongly affect the pharmacokinetics of triptolide and its derivative in rats.
by Xu, Ye
40 Evaluation of different approaches to identifying a higher throughput assay for time-dependent inhibition (TDI).
by Kajbaf, M